William Mikrut
0009-0001-2386-7331
1 paper found
Refreshing results…
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Missing publications? Search for publications with a matching author name.